Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
65.50    0.00 (0.00%)
Bid:
65.00
Ask:
66.00
Spread: 1.00 (1.538%)
Market Cap: £15.96m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Trading Update

20 Jan 2026 07:00

RNS Number : 4533P
MyCelx Technologies Corporation
20 January 2026
 

The information contained within this Announcement is deemed by MYCELX Technologies Corporation to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").

 

20 January 2026

 

MYCELX Technologies Corporation

("MYCELX" or the "Company")

 

MYCELX Achieves Profitability in 2025 Outperforming Market Expectations

 

MYCELX Technologies Corporation (AIM: MYX), the clean water and clean air technology company, is pleased to provide a year-end financial update, reporting expected profitability that significantly exceeds market expectations, along with an update on the Company's strategy for its core markets.

 

The Company expects FY2025 year-end revenue of c.a. $11.7 million, a 140% improvement over FY2024, although slightly less than market expectations of $12.5 million.

 

While EBITDA and profit before tax ('PBT') remain subject to year-end closing procedures, the Company expects EBITDA to be in the region of $680,000, a 131% improvement over FY2024, which includes a gain of $160,000 from the sale of its Saudi Arabia operations, and $520,000 without the gain, compared to market expectations of an EBITDA loss of $200,000.

 

PBT is expected to be in the region of $360,000, including the gain. This materially exceeds the market expectations of a PBT loss of $600,000. Excluding this gain, PBT is c.a. $200,000.

 

This outperformance reflects strict cost discipline, operating leverage, and an increased contribution from higher-margin revenue.

 

Cash and cash equivalents at year-end are $860,000, including $50,000 restricted cash. The Company also expects to collect approximately $4 million in cash during Q1 2026.

 

Current Trading and Outlook

 

We enter 2026 with a stronger earnings profile, a streamlined organization, and increasing commercial momentum across our core markets in the U.S. and internationally. The actions taken in 2024 and executed in 2025 have repositioned the Company for faster customer adoption, multiple project wins, and improved cash generation. Our relationships in the Middle East remain strong, and traction in the U.S. is accelerating following successful trials and deployments with both existing and new customers. We remain disciplined in capital allocation and margin expansion as we scale the business and focus on delivering sustainable, long-term value.

 

While the Company is optimistic about the prospects for 2026 and beyond, at this point in the year the company is maintaining current year guidance and will update the market in due course when there is greater visibility on a number of major contracts.

 

Strategic Update

 

The Company's core markets have been refined to concentrate on Produced Water, PFAS and Water Services (industrial water treatment) as the key focus markets. Produced Water treatment remains the primary focus. PFAS Remediation is slowly evolving into a major market, and the Company is engaged in specific verticals within PFAS that currently have budget to spend. In the case of Water Services, the Company has been selling legacy products into niche applications that add high margin revenue and growing that incremental business will be achieved by expanding roles and repositioning current personnel.

 

The Board was pleased to elevate Matthew Goysich, Director of Engineering, to Executive Vice President and Jim Weidler, to Executive Vice President of Business Development. Both executives have joined the Executive Management team and will attend Board Meetings to provide their insight on our core markets and commercial and strategic plan progress. We congratulate both Matthew and Jim on their well-earned promotions.

 

The Company will make new hires this year in Engineering and Business Development in Q1. The engineering hire will allow Matthew to spend more time with key clients, closing sales and influencing tactics and strategy. Driving our business in the Permian Basin requires an experienced sales professional with relationships and water experience. This initiative and overall sales and marketing reporting and activity will be managed by Jim Weidler.

 

Connie Mixon, CEO, commented:

 

"Achieving profitability represents an important inflection point for MYCELX. Our reputation for delivering advanced technology that economically provides better performance is increasingly recognized among key market players globally. We are excited to continue to vigorously execute our successful strategy to win more business and strengthen our financial profile as we create long-term value for all stakeholders".

 

 

For further information, please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)

Giles Balleny / Callum Davidson / Elysia Bough (Corporate Finance)

Harriet Ward (Corporate Broking)

Jasper Berry / Michael Johnson (Sales)

 

 

 

Tel: +44 20 7220 0500

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTAKCBBDBKDKDD
Date   Source Headline
1st Oct 20157:00 amRNSProgress Update on Trials
10th Sep 20157:00 amRNSHalf Yearly Report
28th Aug 20157:00 amRNSRestricted Common Shares to be Traded in CREST
20th Aug 20157:00 amRNSDirector Resignation
17th Aug 20157:00 amRNSProgress Report on Trials and Cost Reduction
29th Jul 20152:01 pmRNSHolding(s) in Company
22nd Jul 20157:00 amRNSTrading Statement
1st Jul 20157:00 amRNSChange of Adviser
5th Jun 20157:00 amRNSDirector/PDMR Shareholding
28th May 20159:48 amRNSBlocklisting Interim Review
21st May 20153:01 pmRNSDirector/PDMR Shareholding
19th May 20154:01 pmRNSResult of Annual Meeting
19th May 20157:00 amRNSAnnual Meeting Statement
17th Apr 20157:00 amRNSMailing of 2014 Annual Report & Notice of AGM
20th Mar 20157:00 amRNS2014 Preliminary Results
15th Jan 20155:39 pmRNSTrading Update
5th Jan 20157:00 amRNSClose of US Placing
2nd Jan 201512:00 pmRNSHolding(s) in Company
22nd Dec 201412:54 pmRNSHolding(s) in Company
10th Dec 20147:00 amRNSEquity Placing
2nd Dec 20147:00 amRNSEquity Placing
27th Nov 20143:58 pmRNSBlocklisting Interim Review
19th Nov 20147:00 amRNSTrading Statement
12th Sep 20147:00 amRNSHalf Year Results Statement
26th Aug 20147:00 amRNSMiddle East Contract Win
7th Jul 20147:00 amRNSHalf Year Trading Update & Contract Wins
13th May 20143:31 pmRNSResult of Annual Meeting
29th Apr 20144:44 pmRNSBlocklisting Interim Review
22nd Apr 201410:02 amRNSAnnual Report & Accounts Posted
20th Mar 20147:00 amRNS2013 Preliminary Results
30th Jan 20147:00 amRNSYear End Trading Update & Contract Wins
10th Dec 20133:29 pmRNSTotal Voting Rights
4th Dec 20133:24 pmRNSHolding(s) in Company
26th Nov 20137:00 amRNSFast-to-market lease programme yields new leasings
30th Oct 20133:21 pmRNSDirector/PDMR Shareholding
29th Oct 20131:56 pmRNSBlocklisting Interim Review
16th Oct 20133:12 pmRNSDirector Shareholding / Warrant Exercise
3rd Oct 20137:00 amRNSInvestor Presentation
12th Sep 20137:00 amRNSHalf Year Results Statement
19th Aug 20139:06 amRNSNotice of Results
7th Aug 20139:29 amRNSBalance of respective lines of stock
10th Jun 20135:16 pmRNSChange of Main Office Address
3rd Jun 20133:19 pmRNSTotal Voting Rights
28th May 20135:02 pmRNSHolding(s) in Company
28th May 20132:54 pmRNSDirector/PDMR Shareholding
24th May 20138:52 amRNSHolding(s) in Company
14th May 20132:14 pmRNSResult of Annual Meeting
14th May 20137:00 amRNSOperational Update & Directorate Change
9th May 20137:00 amRNSExercise of Warrant
23rd Apr 201312:49 pmRNSApplication for Block Admission

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.